PEGylated hyaluronidase
- Generic Name
- PEGylated hyaluronidase
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 1
- Registration Number
- NCT03979066
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
- Conditions
- Pancreatic Ductal AdenocarcinomaPancreatic CancerPancreatic Neoplasms
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Pancreatic Cancer Research Team
- Target Recruit Count
- 35
- Registration Number
- NCT03634332
- Locations
- 🇺🇸
Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
🇺🇸University of Washington--Seattle Cancer Care Alliance, Seattle, Washington, United States
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
- Conditions
- Cholangiocarcinoma Non-resectableCholangiocarcinoma, IntrahepaticCholangiocarcinoma, ExtrahepaticGallbladder Adenocarcinoma
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT03267940
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
- Conditions
- Pancreatic CancerAdvanced Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT02921022
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT02563548
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
- Conditions
- Adenocarcinoma
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Andrew Ko
- Target Recruit Count
- 3
- Registration Number
- NCT02487277
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT02241187
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 126
- Registration Number
- NCT01959139
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 279
- Registration Number
- NCT01839487
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.